Abstract P1081: Urine Metabolomic Profiles Associated with Incident Heart Failure in Older Adults

S Shinhye Chung (University of Texas Health Science Center at Houston, School of Public Health, Houston, Texas, United States) E Elena Butz (University of Freiburg, Freiburg, Germany) N Ngoc Quynh Nguyen (UTHealth School of Public Health, Houston, Texas, United States) G Guning Liu (The University of Texas Health Science Center at Houston, Houston, Texas, United States) E Eun Hye Moon (UTHealth at Houston, Houston, Texas, United States) R Ron Hoogeveen (BAYLOR COLLEGE MEDICINE, Houston, Texas, United States) C Christie Ballantyne (BAYLOR COLLEGE MEDICINE, Houston, Texas, United States) A Amil Shah (University of Texas Southwestern Medical Center, Dallas (A.S.).) P Paul Kimmel (National Institutes of Health, Bethesda, Maryland, United States) V Vasan Ramachandran (The University of Texas San Antonio School of Public Health, San Antonio, Texas, United States) P Pascal Schlosser A Anna Koettgen (Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, United States) M Morgan Grams (NYU Grossman School of Medicine, New York, New York, United States) J Josef Coresh P Peggy Sekula (University of Freiburg, Friburg, Germany) B Bing Yu (College of Chemistry and Materials Science, Guangdong Provincial Key Laboratory of Supramolecular Coordination Chemistry)

Abstract

Introduction: Metabolomic biomarkers have enhanced heart failure (HF) prediction in addition to clinical risk factors. However, urine metabolites related to incident HF have not been studied. Hypothesis: Novel urine metabolites, as well as uremic toxins, are associated with an increased risk of HF. Methods: Metabolomic profiling was performed in the Atherosclerosis Risk in Communities (ARIC) study at visit 5 using urine samples. Urine metabolite levels were probabilistic quotient normalized prior to the analyses, and 914 known urine metabolites were evaluated with incident HF using Cox proportional hazard regression. Replication analyses were performed on 3,431 participants, including 172 HF cases (mean age=58) from the German Chronic Kidney Disease (GCKD) study (100% Whites). Results: During an average of 7 years of follow-up, 226 incident HF events occurred among 1,242 ARIC participants (54.3% Whites, mean age= 76). After adjusting for clinical risk factors and eGFR, ten urine metabolites were associated with incident HF (FDR p-value <0.05). Guanosine-3',5'-cyclic monophosphate (cGMP), a biologic marker reflecting renal activities of natriuretic peptides, was associated with an increased risk of HF (HR=1.40, 95% CI= 1.21-1.63). Sucrose, a disaccharide composed of glucose and fructose, was also associated with an increased effect on HF (HR=1.30, 95% CI= 1.12-1.50), and the effect persisted with further adjustment of fasting glucose levels. The associations of urine cGMP and sucrose with HF were replicated in GCKD (HR cGMP =1.40, 95% CI= 1.24-1.56; HR sucrose = 1.19, 95% CI= 1.03-1.35, Figure). Additional analyses revealed that cGMP was more strongly associated with HF with reduced (HFrEF) than with preserved ejection fraction (HFpEF), while sucrose was more strongly associated with HFpEF than HFrEF. Conclusions: Urinary metabolites associated with incident HF and its subtypes were identified, providing complementary insights into the molecular mechanism of the development of HF.

Article Details

Journal Circulation
Volume / Issue Vol. 151, Issue Suppl_1
Published March 11, 2025
ISSN 0009-7322
Publisher Lippincott Williams & Wilkins

Journal Info

Circulation

Lippincott Williams & Wilkins

ISSN: 0009-7322 Health Sciences

Authors (16)

S

Shinhye Chung

University of Texas Health Science Center at Houston, School of Public Health, Houston, Texas, United States

E

Elena Butz

University of Freiburg, Freiburg, Germany

N

Ngoc Quynh Nguyen

UTHealth School of Public Health, Houston, Texas, United States

G

Guning Liu

The University of Texas Health Science Center at Houston, Houston, Texas, United States

E

Eun Hye Moon

UTHealth at Houston, Houston, Texas, United States

R

Ron Hoogeveen

BAYLOR COLLEGE MEDICINE, Houston, Texas, United States

C

Christie Ballantyne

BAYLOR COLLEGE MEDICINE, Houston, Texas, United States

A

Amil Shah

University of Texas Southwestern Medical Center, Dallas (A.S.).

P

Paul Kimmel

National Institutes of Health, Bethesda, Maryland, United States

V

Vasan Ramachandran

The University of Texas San Antonio School of Public Health, San Antonio, Texas, United States

P

Pascal Schlosser

A

Anna Koettgen

Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, United States

M

Morgan Grams

NYU Grossman School of Medicine, New York, New York, United States

J

Josef Coresh

P

Peggy Sekula

University of Freiburg, Friburg, Germany

B

Bing Yu

College of Chemistry and Materials Science, Guangdong Provincial Key Laboratory of Supramolecular Coordination Chemistry